FDA Turns Down TransCon PTH; Black Market Hormones; Pandemic Thyroid Tumors

(MedPage Today) -- Denmark's Ascendis Pharma announced that the FDA declined to approve the company's new drug application for the hypoparathyroidism drug palopegteriparatide (TransCon PTH) due to manufacturing concerns. Workdays missed because...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news